Adverum Biotechnologies Inc. (NASDAQ:ADVM) has announced the appointment of Christopher J Morrison as the company’s VP process development, and he will report Angela Thedinga, the company’s Chief Technology Officer.
Christopher Morrison appointed Adverum’s VP process development
Morrison has over 10 years of experience in the pharmaceutical industry with a background in recombinant adeno-associated viral vector process, gene therapy, and clinical manufacturing. He was recently a senior director biopharmaceutical development at ApicBio Therapeutics, having also worked as a senior director at Gemini Therapeutics. Morrison directed the development and implementation of the Phase 1/2 and third phase manufacturing processes at Voyage for various rAAV products of genomic construct and assorted serotypes produced through the Sf9-Baculovirus HEK293 transient transfection production systems.
Thedinga said that Chris will bring vast AAV gene therapy leadership to lead the scaling up of the company’s manufacturing process for ADVM-022. She said that they are delighted to have Chris on Board at Adverum at this pivotal and exciting period as the company continues with the execution of its strategy targeting the delivery of ADVM-022 as soon as possible to patients.
Trillium Therapeutics Appoints Michael Kamarck to Board
Another company that has made a leadership appointment is Trillium Therapeutics Inc (NASDAQ:TRIL), which has appointed Michael Kamark to its Board effective immediately. Michael is a pharmaceutical sector leader with massive experience in manufacturing biologics and broad technical and management experience after serving in several executive leadership roles at different leading pharmaceutical firms over his career spanning 25 years. Currently, he serves as Vir Biotechnology’s Chief Technology Officer, where he is managing a multimodality approach in developing treatments for infectious diseases such as Hepatitis B, Influenza, and the novel coronavirus.
Trillium’s Chairman Robert Kirkman said that they were delighted to have Kamarck on-board to the company’s Board of directors. Kirkman said that Kamarck has a lot of experience and knowledge in biologics development and manufacture and will be of significant value to the company. It prepares to scale up clinical development programs with several second phase programs likely to commence in 2021.
